Alzamend Neuro Inc (ALZN)
$2.12
Performance
- $2.08$2.26$2.12
1.89%
Downside
Day's Volatility :7.96%
Upside
6.19%
- $1.84$40.95$2.12
13.44%
Downside
52 Weeks Volatility :95.52%
Upside
94.82%
Returns
| Period | Alzamend Neuro Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -63.45% | 0.0% |
6 Months | -80.0% | 0.0% |
1 Year | -94.76% | 0.0% |
3 Years | -99.54% | -22.3% |
Highlights
Market Capitalization | 1.8M |
Book Value | - $3.77 |
Earnings Per Share (EPS) | -147.0 |
Wall Street Target Price | 50.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -189.73% |
Return On Equity TTM | -4408.31% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -9.9M |
Diluted Eps TTM | -147.0 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -14.5 |
EPS Estimate Next Year | -14.45 |
EPS Estimate Current Quarter | -2.75 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 2258.49%
Technicals Summary
Sell
Neutral
Buy
Alzamend Neuro Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Alzamend Neuro Inc | 1.44% | -80.0% | -94.76% | -99.54% | -99.9% |
 Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
 Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
 Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
 Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Alzamend Neuro Inc | NA | NA | NA | -14.5 | -44.08 | -1.9 | NA | -3.77 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Alzamend Neuro Inc | Buy | $1.8M | -99.9% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Alzamend Neuro Inc
Vs REGN
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 131.9%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 168.7%
Institutional Holdings
BB&T Corp.
1.83%Vanguard Group Inc
0.93%Geode Capital Management, LLC
0.62%BlackRock Inc
0.47%Virtu Financial LLC
0.31%RFG Advisory Group, LLC
0.20%
Company Information
alzamend neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of alzheimer’s disease, bipolar disorder, major depressive disorder (“mdd”) and post-traumatic stress disorder (“ptsd”). our mission is to rapidly develop and market safe and effective treatments to bring aid to the 43+ million americans suffering from these debilitating diseases. our current pipeline consists of two novel therapeutic drug candidates, al001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and alzn002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat alzheimer’s.
Organization | Alzamend Neuro Inc |
Employees | 4 |
CEO | Mr. Stephan Jackman |
Industry | Miscellaneous |
Discover More
A Spac I Acquisition Corp
$2.12
-3.2%
Keyarch Acquisition Corp
$2.12
-3.2%
Connexa Sports Technologies Inc
$2.12
-3.2%
Us Value Etf
$2.12
-3.2%
First Wave Biopharma Inc
$2.12
-3.2%
Global X Msci Next Emerging
$2.12
-3.2%
Fat Projects Acquisition Corp
$2.12
-3.2%
Capital Link Global Fintech
$2.12
-3.2%
Applied Uv Inc
$2.12
-3.2%